AlloVir, Inc.

NasdaqCM:ALVR Rapporto sulle azioni

Cap. di mercato: US$88.4m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AlloVir Gestione

Gestione criteri di controllo 3/4

AlloVir's Il CEO è Diana Brainard, nominato in May2021, e ha un mandato di 3.25 anni. la retribuzione annua totale è $ 6.06M, composta da 10.3% di stipendio e 89.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.27% delle azioni della società, per un valore di $ 236.69K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.6 anni e 4.1 anni.

Informazioni chiave

Diana Brainard

Amministratore delegato

US$6.1m

Compenso totale

Percentuale dello stipendio del CEO10.3%
Mandato del CEO3.3yrs
Proprietà del CEO0.3%
Durata media del management5.6yrs
Durata media del Consiglio di amministrazione4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Feb 09
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Oct 03
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Jun 23
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Mar 02
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Nov 11
Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir GAAP EPS of $0.69 beats by $1.42

Aug 04

AlloVir stock surges on $126.6M securities offering

Jul 27

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Jul 27
Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21
Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02
We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06
AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01
AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07
This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08
Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04
We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

AlloVir EPS misses by $0.28

Nov 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Diana Brainard rispetto agli utili di AlloVir?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$140m

Mar 31 2024n/an/a

-US$180m

Dec 31 2023US$6mUS$623k

-US$190m

Sep 30 2023n/an/a

-US$169m

Jun 30 2023n/an/a

-US$167m

Mar 31 2023n/an/a

-US$166m

Dec 31 2022US$9mUS$605k

-US$169m

Sep 30 2022n/an/a

-US$189m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$15mUS$365k

-US$172m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$117m

Mar 31 2021n/an/a

-US$91m

Dec 31 2020US$597kn/a

-US$70m

Compensazione vs Mercato: La retribuzione totale di Diana ($USD 6.06M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 679.79K ).

Compensazione vs guadagni: La retribuzione di Diana è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Diana Brainard (52 yo)

3.3yrs

Mandato

US$6,056,943

Compensazione

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Hallal
Executive Chairman of the Board5.9yrsUS$347.00k2.46%
$ 2.2m
Diana Brainard
CEO & Director3.3yrsUS$6.06m0.28%
$ 249.4k
Vikas Sinha
President5.6yrsUS$2.94m0.85%
$ 747.2k
Edward Miller
General Counsel & Secretary5.6yrsUS$1.89m0.37%
$ 327.9k
Brett Hagen
Chief Accounting Officer5.6yrsNessun dato0.063%
$ 55.8k
Ann Leen
Chief Scientific Officer11.6yrsNessun dato2.02%
$ 1.8m
Cintia Piccina
Chief Commercial Officer1.2yrsNessun datoNessun dato

5.6yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di ALVR è esperto e expertise (durata media dell'incarico 5.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Hallal
Executive Chairman of the Board5.9yrsUS$347.00k2.46%
$ 2.2m
Diana Brainard
CEO & Director4.1yrsUS$6.06m0.28%
$ 249.4k
Vikas Sinha
President5.6yrsUS$2.94m0.85%
$ 747.2k
John Mellors
Member of the Scientific Advisory Board1.5yrsNessun datoNessun dato
Malcolm Brenner
Independent Non-Executive Director12.6yrsUS$196.28k0.20%
$ 177.3k
Jeffrey Bornstein
Independent Non-Executive Director4.1yrsUS$211.78k0.066%
$ 58.2k
Michael Boeckh
Member of Scientific Advisory Board1.5yrsNessun datoNessun dato
John DiPersio
Member of Scientific Advisory Board1.5yrsNessun datoNessun dato
Anil Chandraker
Member of Scientific Advisory Board1.5yrsNessun datoNessun dato
Morana Jovan-Embiricos
Independent Non-Executive Director5.3yrsUS$209.28k8.67%
$ 7.7m
Shawn Tomasello
Independent Director2.4yrsUS$200.73k0.031%
$ 27.1k
Juan Vera
Non-Executive Director10.6yrsUS$187.00k2.08%
$ 1.8m

4.1yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALVR sono considerati esperti (durata media dell'incarico 4.1 anni).